| INTEGRATED BIOPHARMA INC | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | Q4-CY2013 | |
| Balance Sheet Date | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2023-Sep-30 | 2023-Jun-30 | 2023-Mar-31 | 2022-Dec-31 | 2022-Sep-30 | 2022-Jun-30 | 2022-Mar-31 | 2021-Dec-31 | 2021-Jun-30 | 2021-Mar-31 | 2020-Dec-31 | 2020-Sep-30 | 2020-Jun-30 | 2020-Mar-31 | 2019-Dec-31 | 2019-Sep-30 | 2019-Jun-30 | 2019-Mar-31 | 2018-Dec-31 | 2018-Sep-30 | 2018-Jun-30 | 2018-Mar-31 | 2017-Dec-31 | 2017-Sep-30 | 2017-Jun-30 | 2017-Mar-31 | 2016-Dec-31 | 2016-Sep-30 | 2016-Jun-30 | 2016-Mar-31 | 2015-Dec-31 | 2015-Sep-30 | 2015-Jun-30 | 2015-Mar-31 | 2014-Dec-31 | 2014-Sep-30 | 2014-Jun-30 | 2014-Mar-31 | 2013-Dec-31 | |||
| Fiscal Period | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q3-FY2023 | Q2-FY2023 | Q1-FY2023 | Q4-FY2022 | Q3-FY2022 | Q2-FY2022 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | Q1-FY2021 | Q4-FY2020 | Q3-FY2020 | Q2-FY2020 | Q1-FY2020 | Q4-FY2019 | Q3-FY2019 | Q2-FY2019 | Q1-FY2019 | Q4-FY2018 | Q3-FY2018 | Q2-FY2018 | Q1-FY2018 | Q4-FY2017 | Q3-FY2017 | Q2-FY2017 | Q1-FY2017 | Q4-FY2016 | Q3-FY2016 | Q2-FY2016 | Q1-FY2016 | Q4-FY2015 | Q3-FY2015 | Q2-FY2015 | Q1-FY2015 | Q4-FY2014 | Q3-FY2014 | Q2-FY2014 | |||
| Price to Sales | |||||||||||||||||||||||||||||||||||||||||||||||||
| Forward Price to Sales MRQ | |||||||||||||||||||||||||||||||||||||||||||||||||
| Price to Book | |||||||||||||||||||||||||||||||||||||||||||||||||
| Price to Earnings | |||||||||||||||||||||||||||||||||||||||||||||||||
| Forward Price to Earnings MRQ | |||||||||||||||||||||||||||||||||||||||||||||||||
| Debt to Asset Ratio | .18x | .21x | .23x | .25x | .27x | .30x | .28x | .29x | .25x | .30x | .28x | .29x | .26x | .39x | .41x | .39x | .44x | .63x | .67x | .71x | .74x | .80x | .84x | .89x | .90x | .94x | .98x | .99x | 1.36x | 1.41x | 1.41x | 1.46x | 1.39x | 1.55x | 1.52x | 1.52x | 1.60x | 1.64x | 1.64x | 1.75x | 1.80x | 1.75x | 1.67x | 1.74x | 1.88x | 1.97x | 1.82x | ||
| Current Ratio | 4.42x | 3.72x | 3.26x | 3.04x | 2.92x | 2.63x | 2.93x | 2.87x | 3.39x | 2.84x | 3.16x | 2.93x | 3.16x | 2.17x | 2.06x | 2.21x | 1.95x | 1.43x | 1.34x | 1.27x | 1.26x | 1.23x | 1.18x | 1.12x | 1.14x | 1.13x | 1.07x | 1.09x | .76x | 1.09x | 1.05x | 1.08x | 1.13x | 1.10x | 1.09x | 1.08x | 1.02x | .95x | .83x | .81x | .79x | .80x | .83x | .81x | .79x | .77x | .83x | ||